Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis

Emmet E McGrath, Allan Lawrie, Helen M Marriott, Paul Mercer, Simon S Cross, Nadine Arnold, Vanessa Singleton, Alfred A R Thompson, Sarah R Walmsley, Stephen A Renshaw, Ian Sabroe, Rachel C Chambers, David H Dockrell, Moira K B Whyte

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

The death receptor ligand tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) shows considerable clinical promise as a therapeutic agent. TRAIL induces leukocyte apoptosis, reducing acute inflammatory responses in the lung. It is not known whether TRAIL modifies chronic lung injury or whether TRAIL has a role in human idiopathic pulmonary fibrosis (IPF). We therefore explored the capacity of TRAIL to modify chronic inflammatory lung injury and studied TRAIL expression in patients with IPF.
Original languageEnglish
Pages (from-to)796-803
Number of pages8
JournalThorax
Volume67
Issue number9
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis'. Together they form a unique fingerprint.

Cite this